title: Metabolic fate of (-)-[4-(3)H]epigallocatechin gallate in rats after oral administration.
abstract: After oral administration of [4-(3)H]EGCg to rats, the radioactivity in blood, major tissues, urine, and feces was measured over time. The radioactivity in blood and most tissues remained low for 4 h postdose, began to increase after 8 h, peaked at 24 h, and then decreased. Major urinary excretion of radioactivity occurred in the 8-24 h period, and the cumulative radioactivity excreted by 72 h was 32.1% of the dose. The radioactivity in the feces was 35.2% of the dose within 72 h postdose. In the case of rats pretreated with antibiotics (antibiotic-pretreated rats), the radioactivity levels of the blood and urine were definitely lower than those in rats not pretreated with antibiotics (normal rats). The radioactivity recovered in the antibiotic-pretreated rat urine was estimated to be only (1)/(100) of that in the normal rat urine. These results clearly demonstrated that the radioactivity detected in the blood and urine of normal rats mostly originated from degradation products of EGCg produced by intestinal bacteria. Furthermore, a main metabolite in the normal rats was purified and identified as 5-(5'-hydroxyphenyl)-gamma-valerolactone 3'-O-beta-glucuronide (M-2). In feces of the normal rats, EGC (40.8% of the fecal radioactivity) and 5-(3',5'-dihydroxyphenyl)-gamma-valerolactone (M-1, 16.8%) were detected. These results suggested that M-1 was absorbed in the body after degradation of EGCg by intestinal bacteria, yielding M-1 with EGC as an intermediate. Furthermore, M-2 was thought to be formed from M-1 in the intestinal mucosa and/or liver, then to enter the systemic circulation, and finally to be excreted in the urine. Taking into account all of the above findings, a possible metabolic route of EGCg orally administered to rats is proposed.
authors.affiliation: Food Research Laboratories, Mitsui Norin Company, Ltd., 223-1 Miyabara, Fujieda City, Shizuoka Prefecture 426-0133, Japan. JDD04347@nifty.ne.jp
authors.forename: T
authors.initials: T
authors.lastname: Kohri
authors.forename: N
authors.initials: N
authors.lastname: Matsumoto
authors.forename: M
authors.initials: M
authors.lastname: Yamakawa
authors.forename: M
authors.initials: M
authors.lastname: Suzuki
authors.forename: F
authors.initials: F
authors.lastname: Nanjo
authors.forename: Y
authors.initials: Y
authors.lastname: Hara
authors.forename: N
authors.initials: N
authors.lastname: Oku
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002392:Catechin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000493:pharmacokinetics; D005243:Feces / Q000737:chemistry; D008297:Male; D011865:Radioisotope Dilution Technique; D051381:Rats; D017208:Rats, Wistar; D013662:Tea; D014556:Urine / Q000737:chemistry
chemical_list: D013662:Tea; D002392:Catechin; C045651:epigallocatechin gallate